VivoSeq
Oncology

Adult Glioblastoma

18

Pipeline Programs↗

4

Active Trials↗

11

Companies Involved↗

Adult Glioblastoma is an emerging landscape with 18 programs across 11 companies. The most active players are Calithera Biosciences, Inc, Eli Lilly, Diakonos Oncology Corporation. 5 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

8/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Calithera Biosciences, Inc

1 program

Phase 1Eli Lilly logo

Eli Lilly

2 programs

Phase 2D

Diakonos Oncology Corporation

2 programs

Phase 2K

Kura Oncology, Inc.

1 program

Phase 2S

SymBio Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

13 of 17 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody318%Vaccine16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.

Analysis

Trial Status

5

clinical trials

Active, not recruiting3 · 60%
Completed1 · 20%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
Completed·TThe Cooper Health System·Phase 1·NCT04552886·17 enrolled
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
Active, not recruiting·UUniversity of Florida·Phase 1·NCT05353530·39 enrolled
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
Active, not recruiting·UUniversity of Florida·Phase 1·NCT06389591·24 enrolled
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02142803·50 enrolled
A Phase I/II Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM), and Recurrent/Progressive Medulloblastoma (MB)
Recruiting·UUniversity of Florida·Phase 1·NCT04573140·28 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)